Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM2275 in Advanced Solid Tumors
NCT07750132Phase 1Recruiting
- Sponsor
- Starmab Biologics
- Start
- Oct 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SM2275 in solid tumor, sponsored by Starmab Biologics. Primary endpoints: Treatment-Emergent Adverse Events at 12 months, Dose-Limiting Toxicities at 21 days and 2 more. Started Oct 2026; status: recruiting.
02
Drugs
SM2275
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07750132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07750132.